Transcriptomic analysis of age-associated periventricular lesions reveals dysregulation of the immune response.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/167668/

Version: Published Version

Article:
Fadul, M.M. orcid.org/0000-0002-2208-9988, Heath, P.R., Cooper-Knock, J.
orcid.org/0000-0002-0873-8689 et al. (8 more authors) (2020) Transcriptomic analysis of age-associated periventricular lesions reveals dysregulation of the immune response. International Journal of Molecular Sciences, 21 (21). 7924. ISSN 1661-6596

https://doi.org/10.3390/ijms21217924

Reuse
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
Transcriptomic Analysis of Age-Associated Periventricular Lesions Reveals Dysregulation of the Immune Response

Motaz M. Fadul 1*, Paul R. Heath 1**, Johnathan Cooper-Knock 1**, Julian M. Kurz 1**, Hayder A. Al-Azzawi 1, Zarki Ali 1, Taylor Smith 1, Fiona E. Matthews 2,3, Carol Brayne 2, Stephen B. Wharton 1,*† and Julie E. Simpson 1,**† on behalf of the Cognitive Function and Ageing Neuropathology Study Group

1 Sheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield S10 2HQ, UK; mmfadul1@sheffield.ac.uk (M.M.F.); p.heath@sheffield.ac.uk (P.R.H.); j.cooper-knock@sheffield.ac.uk (J.C.-K.); jmkurz1@sheffield.ac.uk (J.M.K.); haal-azzawil@sheffield.ac.uk (H.A.A.-A.); zali7@sheffield.ac.uk (Z.A.); tsmith11@sheffield.ac.uk (T.S.); s.wharton@sheffield.ac.uk (S.B.W.)
2 Institute of Public Health, University of Cambridge, Cambridge CB2 0SR, UK; Fiona.Matthews@newcastle.ac.uk (F.E.M.); cb105@medschl.cam.ac.uk (C.B.)
3 Institute of Health and Society, University of Newcastle, Newcastle upon Tyne NE4 5PL, UK
* Correspondence: julie.simpson@sheffield.ac.uk; Tel.: +44-114-222-2242
† Joint senior authors.

Received: 28 September 2020; Accepted: 23 October 2020; Published: 25 October 2020

Abstract: White matter lesions (WML) are a common feature of the ageing brain associated with cognitive impairment. The gene expression profiles of periventricular lesions (PVL, n = 7) and radiologically-normal-appearing (control) periventricular white matter cases (n = 11) obtained from the Cognitive Function and Ageing Study (CFAS) neuropathology cohort were interrogated using microarray analysis and NanoString to identify novel mechanisms potentially underlying their formation. Histological characterisation of control white matter cases identified a subgroup (n = 4) which contained high levels of MHC-II immunoreactive microglia, and were classified as “pre-lesional.” Microarray analysis identified 2256 significantly differentially-expressed genes (p ≤ 0.05, FC ≥ 1.2) in PVL compared to non-lesional control white matter (1378 upregulated and 878 downregulated); 2649 significantly differentially-expressed genes in “pre-lesional” cases compared to PVL (1390 upregulated and 1259 downregulated); and 2398 significantly differentially-expressed genes in “pre-lesional” versus non-lesional control cases (1527 upregulated and 871 downregulated). Whilst histological evaluation of a single marker (MHC-II) implicates immune-activated microglia in lesion pathology, transcriptomic analysis indicates significant downregulation of a number of activated microglial markers and suggests established PVL are part of a continuous spectrum of white matter injury. The gene expression profile of “pre-lesional” periventricular white matter suggests upregulation of several signalling pathways may be a neuroprotective response to prevent the pathogenesis of PVL.

Keywords: periventricular lesions; transcriptomic profiling; nanostring; immune response

1. Introduction

Age-associated white matter lesions (WML) appear as hyperintensities on T2-weighted magnetic resonance images (MRI) and are frequently observed in people aged over 65 years [1]. These WML are...
often interpreted as a surrogate for small vessel disease and are associated with an increased risk of dementia [2–4]; the impact of WML on cognition is related to their neuroanatomical locations [5].

WML can be subclassified as periventricular (PVL) or deep subcortical lesions (DSCL), which both share similar histopathological features, including myelin attenuation, axonal damage, astrogliosis and microglial activation, as reviewed in [6–8]. However, differences in the cellular pathology profiles of these WML have also been reported, particularly in relation to their microglial phenotype. Microglia share functions with tissue macrophages, including surveillance, antigen presentation and phagocytosis [9]. Previous studies suggest microglia within PVL have a predominantly pro-inflammatory immune reactive phenotype, associated with the expression of the major histocompatibility complex class II (MHC-II) and co-stimulatory molecule B7-2 (CD80) [10], while microglia within DSCL have a phagocytic phenotype associated with the abundance of CD68+ amoeboid microglia [11,12].

The exact mechanism(s) underlying the pathogenesis of WML remains unknown. However chronic cerebral hypoperfusion [13,14], dysfunction of the blood brain-barrier (BBB) [15–17] and cortical pathologies have been linked to their formation [18]. WML show arteriolar thickening, perivascular widening, capillary loss and perivenous collagenosis, with DSCL in particular associated with the expression of high levels of a number of hypoxia response molecules, suggesting that vascular insufficiency and consequent hypoperfusion underlie their formation [13]. This is further supported by transcriptomic profiling of DSCL, which has confirmed increased expression of hypoxia-related genes, and also identified dysregulation of immune-regulatory genes, including those involved with antigen presentation, pro-inflammatory cytokine signalling and phagocytosis [19].

Transcriptomic analyses enable the identification of relevant gene expression changes that are often missed in targeted approaches. While histological studies suggest BBB dysfunction, serum protein accumulation and microglial activation underlie the pathogenesis of PVL [10,15,20], to date no studies have employed transcriptomic analysis to characterise their profile. Therefore, the current study interrogated the gene expression profile of PVL using two independent approaches to identify novel mechanisms potentially underlying their formation.

2. Results

2.1. Histological Characterisation of Periventricular White Matter

MRI of the formalin-fixed hemisphere was used to guide sampling of the contralateral frozen periventricular white matter, and histological characterisation of the sampled frozen blocks was performed to confirm the tissue status as non-lesional control periventricular white matter or PVL. These frozen blocks were then sampled for transcriptomic analysis. All non-lesional control cases displayed preservation of myelin throughout the periventricular region and an intact ependymal lining (Figure 1A,B,D,E). In contrast, all PVL cases were characterised by a reduction in luxol fast blue (LFB) staining, indicative of myelin attenuation (Figure 1C), and partial denudation of the ependyma in four out of seven of the cases (Figure 1F).

To further characterise the periventricular white matter samples, activated microglia were visualised using MHC-II, which immunolabelled the microglial cell body and proximal processes. Seven cases of radiologically and histologically-rated non-lesional control white matter contained low levels of MHC-II immunoreactive microglia throughout the periventricular region (Figure 1G); however, four cases contained high levels of MHC-II expression (Figure 1H). While the MRI and histological characterisation had indicated that there was no demyelination, the immunoreactive profile of MHC-II suggested microglial activation; therefore, the non-lesional group was subsequently subdivided into non-lesional control (no demyelination; low levels of MHC-II immunoreactivity, n = 7) and “pre-lesional” cases (no demyelination; high levels of MHC-II+ microglia, n = 4). Seven cases of radiologically and histologically-identified PVL contained high levels of MHC-II+ microglia (Figure 1I).
Figure 1. Histological characterisation of periventricular white matter. Luxol fast blue (LFB) (A,B) and H&E staining (D,E) of radiologically normal appearing white matter demonstrated a regular pattern of myelin staining across the periventricular region. In contrast, LFB (C) and H&E staining (F) of radiologically identified lesional cases displayed a band of periventricular demyelination. MHC-II immunostaining of radiologically normal appearing white matter identified cases with minimal MHC-II$^+$ microglia ((G), control) but also cases with high levels of MHC-II immunoreactivity ((H), “pre-lesional”). Radiologically identified periventricular lesions (PVL) contained high levels of MHC-II$^+$ microglia (I). Scale bar represents 500 µm in (A–F) and 100 µm in (G–I).

2.2. Microarray Analysis

Based on the bioanalyser RNA quality profile, transcriptomic analysis of 18 periventricular white matter cases (seven control, four “pre-lesional” and seven PVL) was performed using Human Genome U133 Plus 2.0 Arrays, which contain at least one probe for each gene and recognize over 39,000 genes. Principal component analysis (PCA) showed clear separation of the three groups and confirmed there were no sample outliers (Figure 2); quality control (QC) measures were within an acceptable range. After setting the stringency parameters to fold change $\geq 1.2$ and $p$ value $\leq 0.05$, 2256 genes were significantly differentially expressed in PVL compared to non-lesional control (1378 upregulated and 878 downregulated); 2649 were significantly differentially-expressed genes in “pre-lesional” cases compared to PVL (1390 upregulated and 1259 downregulated); and 2398 genes were significantly differentially expressed in “pre-lesional” versus non-lesional control cases (1527 upregulated and 871 downregulated). The microarray datasets are freely available at the Gene Expression Omnibus (GEO) public database (accession code GSE157363).
Figure 2. Principle component analysis (PCA) of ageing periventricular transcriptomic datasets. The PCA plot of control (blue), “pre-lesion” (yellow) and PVL (pink) shows a separation of differentially-expressed genes between the groups.

In PVL compared to non-lesional control periventricular white matter, functional grouping analysis with the highest stringency settings identified enrichment of genes that were associated with MHC antigen processing and presentation, major histocompatibility II receptor activity and collagen IV. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis in the Database for Annotation, Visualization and Integrated Discovery (DAVID) identified 53 significantly dysregulated pathways (Supplementary Materials, Table S1), including immune response-associated pathways (Table 1). In PVL, genes associated with antigen processing and presentation (MHC-II) were significantly downregulated, including HLA-DRA (probeset 210982_s_at, FC = −1.71, \( p = 0.0038 \)) and CD74 (probeset 1567627_at, FC = −2.67, \( p = 0.0068 \)). Significant downregulation of genes associated with the phagosome was also detected, including FCGR1A (probeset 216951_at, FC = −2.12, \( p = 0.0164 \)).

Table 1. KEGG pathway analysis of PVL versus control white matter transcriptomic datasets.

| Pathway                                           | Count | \( p\)-Value |
|---------------------------------------------------|-------|--------------|
| hsa04612: Antigen processing and presentation      | 20    | \( 9.17 \times 10^{-6} \) |
| hsa04145: Phagosome                               | 24    | 0.003        |
| hsa04672: Intestinal immune network for IgA production | 11    | 0.004        |
| hsa04662: B cell receptor signalling pathway       | 12    | 0.026        |

In “pre-lesional” compared to non-lesional control periventricular white matter, functional grouping analysis revealed enrichment of genes associated with calcium signalling, glutamate receptor activity, GABA receptor activity and MHC classes I/II-like antigen recognition protein. KEGG pathway analysis identified 79 significantly dysregulated pathways (Supplementary Materials, Table S2), including immune response-associated signalling pathways (including calcium, cAMP and MAPK) and synaptic pathways (including glutamatergic, dopaminergic and cholinergic synapses) (Table 2). In “pre-lesional” cases, multiple genes associated with the phagosome, antigen processing and antigen presentation were downregulated, including HLA-DPA1 (probeset 213537_at, FC = −2.72, \( p = 0.0004 \)) and HLA-DQB1 (probeset 211654_x_at, FC = −1.76, \( p = 0.0046 \)). Upregulation of multiple genes associated with calcium signalling and synaptic signalling was found, including calcium voltage-gated channel subunit alpha 1E (CACNA1EI) (probeset 236013_at, FC = 4.46, \( p = 0.001 \); probeset 244256_at, FC = 4.11, \( p = 0.001 \); probeset 240650_at,
FC = 1.31, p = 0.016; probeset 208432_s_at, FC = 1.62, p = 0.012) and calcium/calmodulin-dependent protein kinase IV (CAMK4) (probeset 229029_at, FC = 2.74, p = 0.0008; probeset 241871_at, FC = 3.31, p = 0.0008), along with upregulation of genes associated with GABAergic synaptic signalling, including gamma-aminobutyric acid (GABA) A receptor alpha 5 GABRA5 (probeset 206456_at, FC = 7.1, p = 0.0002; probeset 215531_s_at, FC = 3.89, p = 0.001; probeset 217280_x_at, FC = 1.6, p = 0.009).

Table 2. KEGG pathway analysis of “pre-lesional” versus control white matter transcriptomic datasets.

| Pathway                                      | Count | p-Value         |
|----------------------------------------------|-------|-----------------|
| hsa04020:Calcium signalling pathway          | 42    | 3.38 × 10⁻⁹     |
| hsa04728:Dopaminergic synapse                | 34    | 5.29 × 10⁻⁹     |
| hsa04724:Glutamatergic synapse               | 30    | 6.28 × 10⁻⁸     |
| hsa04725:Cholinergic synapse                 | 29    | 1.29 × 10⁻⁷     |
| hsa04727:GABAergic synapse                   | 23    | 1.82 × 10⁻⁶     |
| hsa04612:Antigen processing and presentation | 20    | 1.58 × 10⁻⁵     |
| hsa04024:cAMP signalling pathway             | 34    | 1.54 × 10⁻⁴     |
| hsa04010:MAPK signalling pathway             | 40    | 2.23 × 10⁻⁴     |
| hsa04145:Phagosome                          | 25    | 0.002           |
| hsa04062:Chemokine signalling pathway        | 28    | 0.005           |
| hsa04151:PI3K-Akt signalling pathway         | 45    | 0.005           |
| hsa04660:T cell receptor signalling pathway  | 17    | 0.011           |
| hsa04662:B cell receptor signalling pathway  | 13    | 0.014           |
| hsa04068:FoxO signalling pathway             | 19    | 0.038           |

In “pre-lesional” periventricular white matter compared to PVL, functional grouping analysis identified an enrichment of genes associated with GABA receptor activity, adenylate cyclase activity, metallothionein and neurotransmitter gated ion channels. KEGG pathway analysis identified 38 significantly dysregulated pathways (Supplementary Materials, Table S3), including signalling pathways (including calcium, cAMP, cGMP and MAPK) and synaptic pathways (including glutamatergic, GABAergic and dopaminergic synapses) (Table 3). Significant upregulation of multiple genes encoding the calcium signalling pathway was detected in “pre-lesional” periventricular white matter, including upregulation of calmodulin 1 and calmodulin 2 (CALM1 and CALM2) (probeset 213688_at, FC = 1.59, p = 0.016) and calcium/calmodulin-dependent protein kinase II alpha (CAMKK2) (probeset 213108_at, FC = 1.67, p = 0.043; probeset 207613_s_at, FC = 7.06, p = 0.008); and upregulation of genes associated with glutamatergic signalling, including glutamate receptor, ionotopic, N-methyl D-aspartate 1 (GRIN1) (probeset 205915_x_at, FC = 1.45, p = 0.011; probeset 211125_x_at, FC = 1.65, p = 0.041; probeset 210781_x_at, FC = 1.82, p = 0.018), glutamate receptor, ionotopic, AMPA 2 (GRIA2) (probeset 241172_at, FC = 1.55, p = 0.015) and GRIA3 (probeset 1569290_s_at, FC = 1.6, p = 0.017; probeset 217565_at, FC = 1.87, p = 0.021; probeset 208032_s_at, FC = 2.38, p = 0.0005; probeset 230144_at, FC = 2.66, p = 0.004; probeset 206730_at, FC = 2.94, p = 0.006).
### Table 3. KEGG pathway analysis of “pre-lesional” versus PVL transcriptomic datasets.

| Pathway                                      | Count | \( p \)-Value  |
|----------------------------------------------|-------|----------------|
| hsa04020: Calcium signalling pathway         | 46    | \( 4.71 \times 10^{-11} \) |
| hsa04724: Glutamatergic synapse              | 29    | \( 3.97 \times 10^{-7} \)   |
| hsa04727: GABAergic synapse                  | 21    | \( 3.58 \times 10^{-5} \)   |
| hsa04725: Cholinergic synapse                | 23    | \( 2.30 \times 10^{-4} \)   |
| hsa04310: Wnt signalling pathway             | 26    | \( 3.83 \times 10^{-4} \)   |
| hsa04024: cAMP signalling pathway            | 33    | \( 5.36 \times 10^{-4} \)   |
| hsa0422: cGMP-PKG signalling pathway         | 28    | \( 5.96 \times 10^{-4} \)   |
| hsa04728: Dopaminergic synapse               | 22    | 0.0039                |
| hsa04010: MAPK signalling pathway            | 34    | 0.0143                |

---

### 2.3. EnrichR

The top 1000 significantly differentially-expressed genes in the PVL versus control non-lesional white matter dataset were imported into EnrichR to check their relationships with KEGG pathways, biological processes, panther pathways and the human gene atlas. The top pathway or functional group identified in each analysis included: antigen processing and presentation (KEGG pathway \( p = 6.77 \times 10^{-6} \)); inflammation (panther pathway, \( p = 0.0001 \)); and MHC-II (cellular component \( p = 0.0001 \)). The top 10 pathways/functional groups identified by EnrichR are shown in Table 4.

### Table 4. Enrich R analysis of PVL versus control non-lesional white matter transcriptomic datasets. The top 10 pathways/functional groups identified by the analysis are shown below.

| Pathway/Functional Group | \( p \)-Value  |
|--------------------------|----------------|
| KEGG pathway             |                |
| hsa04612: Antigen processing and presentation | \( 6.77 \times 10^{-6} \) |
| hsa05169: Epstein-Barr virus infection        | \( 1.06 \times 10^{-4} \) |
| hsa05215: Prostate cancer                      | \( 1.49 \times 10^{-4} \) |
| hsa05140: Leishmaniasis                        | \( 4.58 \times 10^{-4} \) |
| hsa05168: Herpes simplex infection             | \( 8.04 \times 10^{-4} \) |
| hsa05332: Graft-versus-host disease             | \( 8.61 \times 10^{-4} \) |
| hsa04940: Type I diabetes mellitus             | 0.0012 |
| hsa04915: Estrogen signalling pathway           | 0.0015 |
| hsa05330: Allograft rejection                  | 0.003 |
| hsa05164: Influenza A                           | 0.0031 |

| Panther pathway          |                |
|--------------------------|----------------|
| P00031: Inflammation mediated by chemokine and cytokine signalling | \( 1.20 \times 10^{-4} \) |
| P00053: T cell activation                                      | 0.0068 |
| P02756: N-acetylglucosamine metabolism                        | 0.0199 |
| P02776: Serine glycine biosynthesis                           | 0.0199 |
| P00010: B cell activation                                      | 0.0217 |
| P00007: Axon guidance mediated by semaphorins                 | 0.0257 |
| P00049: Parkinson disease                                      | 0.0359 |
| P00054: Toll receptor signalling pathway                       | 0.0391 |
| P00006: Apoptosis signalling pathway                           | 0.0426 |
| P04386: Histamine H2 receptor mediated signalling pathway      | 0.0443 |

| Gene Ontology (cellular component)                          |                |
|--------------------------------------------------------------|----------------|
| GO:0042613: MHC class II protein complex                      | \( 1.24 \times 10^{-4} \) |
| GO:0016607: nuclear speck                                     | \( 3.02 \times 10^{-4} \) |
| GO:0045121: membrane raft                                     | \( 4.73 \times 10^{-4} \) |
| GO:0012507: ER to Golgi transport vesicle membrane            | \( 5.67 \times 10^{-4} \) |
| GO:0030671: clathrin-coated phagocytic vesicle membrane       | \( 9.54 \times 10^{-4} \) |
| GO:0016606: LYSIP100-associated nuclear domain               | 0.0022 |
| GO:0010445: nuclear dicing body                               | 0.0022 |
| GO:0071601: sphere organelle                                  | 0.0022 |
| GO:0016604: nuclear body                                      | 0.0022 |
| GO:0035363: histone locus body                                | 0.0023 |
2.4. Computational Deconvolution of Microglial Gene Expression

To focus the results on changes in the microglial phenotype, bone marrow stromal cell antigen 2 (BST2), also referred to as CD317 or tetherin, was used to identify the co-expressed genes associated with inactivated microglia (group A), while for activated microglia, TREM2, HLA-DRA, ENTPD1, CD80, CD86, CCR5, CD274, ITGAX, TIMD4 and MRC1 were selected (group B). In both activated and inactivated microglia groups, 17 genes were co-expressed with the gene set selected (Table 5), which showed similar patterns of expression in the three groups: non-lesional control, “pre-lesion” and PVL (Figure 3). Overall analysis of the co-expressed genes suggested similar levels of activated and inactivated microglia within PVL and “pre-lesions” compared to non-lesional control white matter, with the exception of CD80 which showed a marked decrease in expression in PVL (Figure 3).

Table 5. Microglial deconvolution. BST2 (CD317) was used to identify the co-expressed genes associated with inactivated microglia (group A), while for activated microglia TREM2, HLA-DRA, ENTPD1, CD80, CD86, CCR5, CD274, ITGAX, TIMD4 and MRC1 were selected (group B).

| Group A (Inactivated Microglia) | Group B (Activated Microglia) |
|--------------------------------|-------------------------------|
| ISG15                         | HLA-DPB1                      |
| MX1                           | HLA-DQB1                      |
| IFI44L                        | MX1                           |
| OAS2                          | HLA-DPA1                      |
| IFI35                         | OAS1                          |
| OAS1                          | LCP2                          |
| LY6E                          | FCER1G                        |
| IFIT1                         | GBP5                          |
| IFIT4                         | CYBB                          |
| UBE2L6                        | SAMSNI                        |
| IFIT3                         | SLAMF8                        |
| IRF7                          | MS4A6A                        |
| XAF1                          | IGSF6                         |
| RSAD2                         | HAVCR2                        |
| OAS3                          | TFEC                          |
| IRF9                          | CD163                         |
| USP18                         | FCGR2A                        |
|                               | MSR1                          |
Figure 3. Graphical representation of gene annotations in activated and inactivated microglia in ageing periventricular white matter. BST2 was used to identify the co-expressed genes associated with inactivated microglia (A–A3). For activated microglia, TREM2, HLA-DRA, ENTPD1, CD80, CD86, CCR5, CD274, ITGAX, TIMD4 and MRC1 were selected (B–B3). C: non-lesional control white matter; P: “pre-lesional”; L: periventricular lesion.
2.5. Validation of Candidate Gene Expression by NanoString nCounter

Nanostring is a hybridisation-multiplex digital technology which uses capture probes and unique color-coded barcode reporter probes to measure a broad range of mRNA in a single reaction without the need of reverse transcription of mRNA or amplification of cDNA.

NanoString data analysis was employed to validate a panel of candidate gene expression changes identified in the microarray analysis of PVL versus non-lesional control white matter. NanoString analysis confirmed the significant differential expression of seven genes (CCL3 $p = 0.008$; CCR5 $p = 0.0002$; CD74 $p = 0.013$; CX3CR1 $p = 0.01$; IL1B $p = 0.0007$; JUN $p = 0.008$; PTGS2 $p = 0.007$), and identified 19 genes which showed the same directional changes to the microarray findings, although not reaching statistical significance (Table 6).

| Gene   | Microarray Fold Change | $p$-Value | NanoString Fold Change | $p$-Value |
|--------|------------------------|-----------|------------------------|-----------|
| AKT3   | 1.33                   | 0.002 **  | 1.52                   | 0.127     |
| CCL2   | −1.7                   | 0.05 *    | −1.88                  | 0.290     |
| CCL3   | −1.31                  | 0.05 *    | −16.11                 | 0.008 **  |
| CCL4   | −1.16                  | 0.060     | −5.14                  | 0.098     |
| CCR5   | −1.49                  | 0.01 *    | −2.17                  | 0.0003 ***|
| CD163  | −3.27                  | 0.315     | −1.07                  | 0.928     |
| CD74   | −2.67                  | 0.006 **  | −1.54                  | 0.013 *   |
| CD8A   | −1.28                  | 0.016 *   | −1.23                  | 0.567     |
| COL6A3 | −1.62                  | 0.01 *    | −1.72                  | 0.074     |
| CX3CR1 | −1.5                   | 0.005 **  | −1.64                  | 0.01 *    |
| CYBB   | −1.62                  | 0.013 *   | −1.17                  | 0.577     |
| EPSTI1 | −1.31                  | 0.839     | −1.39                  | 0.101     |
| FCER1G | −1.52                  | 0.076     | −1.28                  | 0.265     |
| FGL2   | −1.77                  | 0.012 *   | −1.29                  | 0.190     |
| FPR1   | −2.39                  | 0.017 *   | −2.82                  | 0.066     |
| HLA-DRA| −1.71                  | 0.004 **  | −1.51                  | 0.071     |
| IFNAR1 | 1.79                   | 0.004 **  | 1.25                   | 0.190     |
| IGSF6  | −1.27                  | 0.257     | −1.12                  | 0.585     |
| IKKB   | 1.38                   | 0.839     | 1.88                   | 0.097     |
| IL1A   | −1.06                  | 0.206     | −1.71                  | 0.061     |
| IL1B   | −1.34                  | 0.01 *    | −4.72                  | 0.007 **  |
| IRF7   | 1.04                   | 0.673     | −1.04                  | 0.846     |
| JUN    | 1.33                   | 0.008 **  | 1.98                   | 0.008 **  |
| MSR1   | −1.95                  | 0.023 *   | −1.06                  | 0.877     |
| OAS1   | −1.12                  | 0.83      | 1.14                   | 0.644     |
| PHF21A | 1.36                   | 0.008 **  | 1.5                    | 0.121     |
| PTGS2  | −1.3                   | 0.011 *   | −2.59                  | 0.007 **  |
| RSAD2  | −1.2                   | 0.065     | 1.09                   | 0.757     |
| SLAMF8 | −1.03                  | 0.679     | −1.48                  | 0.327     |

* $p \leq 0.05$, ** $p \leq 0.01$, *** $p \leq 0.001$, down-regulated transcripts (pink), up-regulated transcripts (green).

2.6. Validation of Candidate Gene Expression by Immunohistochemistry

To further validate our transcriptomic findings, we selected a panel of four biologically relevant genes from pathways highlighted by both the microarray and NanoString datasets (CD74, IL1B, CD163, CD86). Expression of proteins encoded by the genes of interest were examined by immunohistochemistry (Figure 4), and the immunoreactive area of CD74, IL-1β, CD163 and CD86 staining in the periventricular white matter was quantified within each group (Table 7). CD74 immunolabelled microglia with a ramified
morphology and were mainly present in the non-lesional control group (Figure 4A–C). Expression of CD74 significantly differed across the three groups \((p = 0.002)\), with non-lesional control periventricular white matter containing significantly higher levels of CD74 immunoreactivity compared to both “pre-lesional” \((p = 0.033)\) and PVL \((p = 0.003)\) (Figure 5A). IL-1β, CD163 and CD86 immunoreactivity was predominantly associated with the cell bodies and extending processes of cells morphologically resembling microglia. Expression of IL-1β \((p = 0.7)\), CD163 \((p = 0.38)\) and CD86 \((p = 0.63)\) immunoreactivity did not significantly vary across the three groups (Figure 5B–D).

![Figure 4. Histological validation candidate gene expression changes. Expression of proteins encoded by candidate genes highlighted by both microarray and NanoString datasets was assessed. (A–C) CD74, (D–F) IL-1β, (G–I) CD163 and (J–L) CD86 immunolabelled cell bodies and processes of microglia in all periventricular white matter groups: non-lesional control white matter (A,D,G,J); “pre-lesional” white matter (B,E,H,K); and PVL (C,F,I,L). Scale bar represents 100 µm.](image-url)
Table 7. Expression of CD74, IL-1β, CD163 and CD86 in ageing periventricular white matter. The percentage area of immunoreactivity of each of the markers is shown, median (IQR).

| WM Group | Control     | Pre-Lesional | PVL         |
|----------|-------------|--------------|-------------|
| CD74     | 3.47 (3.08–4.15) | 1.66 (0.9–2.14) | 1.3 (1.13–1.66) |
| IL-1β    | 3.87 (1.91–4.86) | 2.76 (1.91–4.07) | 3.43 (2.48–4.22) |
| CD163    | 0.93 (0.75–1.21) | 0.39 (0.29–1.08) | 0.95 (0.59–1.32) |
| CD86     | 4.55 (4.52–5.66) | 5.34 (3.98–6.23) | 5.04 (3.35–6.03) |

IQR: inter-quartile range.

Figure 5. Quantitation of the expression of candidates in periventricular ageing white matter. The percentage area immunoreactivity of the protein encoded by a panel of candidate genes was assessed in the three periventricular white matter groups. (A) CD74 expression was significantly higher in non-lesional control periventricular white matter compared to both “pre-lesional” (p = 0.033) and PVL (p = 0.003). The immunoreactive profiles of (B) IL-1β, (C) CD163 and (D) CD86 did not significantly differ across the three groups. * p < 0.05, *** p < 0.005.

3. Discussion

Age-associated WML correlate with reductions in information processing speed and executive function, and are associated with an increased risk of developing dementia [8,21]. Histological characterisation and transcriptomic profiling of DSCL suggest that vascular insufficiency and hypoperfusion underlie their formation [13], but to date no comparable studies have interrogated the gene expression profile of PVL.
The current study employed two independent approaches to characterise the transcriptomic signature of PVL, aiming to identify potential mechanisms underlying their pathogenesis. We demonstrate that established, demyelinated PVL are associated with dysregulation of the immune response, whilst increased signalling is a feature of “pre-lesional” periventricular white matter and may represent attempts to prevent lesion formation.

PVL are characterised by dysfunction of the BBB and significant levels of immune-activated MHC-II+ microglia [10,15,17], suggesting that a loss of cerebrovascular integrity and the resulting microglial activation contribute to lesion pathology. In the current study, radiologically identified PVL and non-lesional control periventricular white matter cases underwent histological validation, including assessment of MHC-II immunoreactivity, prior to transcriptomic profiling. As expected, demyelination and MHC-II+ microglia are prominent features of PVL; however, a subgroup of radiologically normal periventricular white matter cases were identified, which showed no evidence of demyelination but contained moderately high levels of MHC-II+ microglia. The transcriptomic profile of these cases was subsequently assessed independently and termed “pre-lesional,” although it should be acknowledged that it cannot be definitively known whether these cases would have progressed to develop clinically relevant PVL. Extensive detailed histological characterisation studies are required to fully elucidate the profile of these “pre-lesions”.

Microarray analysis indicates that the transcriptome of “pre-lesional” cases is distinct from radiologically and histologically control-grade white matter from non-lesional cases, and similarly to PVL, is associated with the dysregulation of immune function-associated genes. In contrast to increased immunohistochemical detection of MHC-II, several HLA-associated transcripts are significantly down-regulated in both “pre-lesion” and PVL compared to non-lesional control white matter. It should, however, be noted that mRNA and protein expression can be decoupled in time [22,23], and that transcriptomic profiling of post-mortem tissue indicates the gene expression profile at one timepoint. While this discordant result appears to argue against the use of transcriptomic profiling technologies to identify potential biologically relevant gene expression changes, it has been shown that differentially-expressed transcripts have significantly higher correlations between mRNA and protein levels when compared to transcripts that are not differentially expressed [23], giving confidence for the use of mRNA profiling in the current study. Indeed CD74—a protein that associates with MHC-II and is an important chaperone that regulates antigen presentation for the immune response—is significantly down-regulated in “pre-lesional” cases and PVL, at both the mRNA and protein levels.

As gene expression profiling was conducted on total tissue extracts, which may have masked cell-specific changes in the transcriptome, we performed a computational deconvolution to interrogate changes in gene expression specific to microglial phenotypes within “pre-lesions” and PVL. BST2 (CD317) is associated with inactivated microglia [24] and diminishes the expression of inflammatory genes [25]; therefore, BST2 was selected to identify the co-expressed genes associated with inactivated microglia. The phenotypic transformation from homeostatic microglia towards reactive microglia in dementia pathologies is associated with TREM2 [26], HLA-DRA [27], ENTPD1 (CD39) [28], CD80 (B7-1) [29], CD86 (B7-2) [10], CCR5 [30], CD274 [31], ITGAX (CD11c) [32], TIMD4 [33] and MRC1 [34]. Therefore, these candidates were used in the deconvolution analysis to identify co-expressed genes associated with active microglia in “pre-lesions” and PVL. Overall, our data are consistent with similar levels of both active and inactive-associated microglial transcripts being present in both “pre-lesions” and PVL, with the exception of CD80 (expressed by antigen presenting cells), which showed a marked decrease in expression in PVL. Overall, our data demonstrate a heterogeneous microglial population within periventricular white matter, highlighting the microglial diversity in the periventricular regions of the ageing brain and the need to examine an extensive panel of markers when assessing the microglial phenotype.

Expression of a panel of candidate gene expression changes identified in the microarray analysis of PVL compared to control white matter was validated using NanoString. This novel, robust profiling
technology has the ability to analyse low RNA quality and enables the quantification of mRNA without
the use of reverse transcription or amplification of cDNA [35], which is advantageous when assessing
post-mortem material. In PVL compared to the non-lesional control group, 65% of the genes assessed
displayed a non-significant but similar directional change between both platforms, and 24% of the genes
revealed a significant difference with similar directional change, validating the findings of the array
analysis. Among the validated gene expression changes, significant down-regulation of the chemokine
receptors CCR5 and CX3CR1, the chemokine CCL3 and pro-inflammatory cytokine IL1B are features of
established PVL. Expressions of these chemoattractant cytokines and receptors are a prominent feature
of active multiple sclerosis lesions and their animal models, where they are primarily associated with
active microglia and ongoing demyelination [36–38]; in contrast, their levels significantly decrease in
established PVL.

Cerebral white matter supports the bidirectional transfer of signals between the cortex and subcortical
structures, where dysregulation of signalling impacts communication and cognitive function [21].
Comparison of the transcriptomic profile of “pre-lesional” white matter with both control white matter and
PVL indicates significant upregulation of signalling and synaptic pathways. Loss of white matter integrity
following ischaemic stroke in aged mice is mainly attributed to Ca2+ dyshomeostasis, which ultimately
induces oligodendrocyte loss and axonal disruption [39]; therefore, the significant increase in calcium
signalling in “pre-lesional” white matter may represent a potential neuroprotective mechanism to
prevent lesion formation. Axons release vesicles containing glutamate during the propagation of action
potentials [40]. Glutamate receptors are expressed by mature oligodendrocytes [41], and communication
between axons and myelin has led to the axon–myelin–synapse hypothesis [42], wherein glutamate
signalling is a mechanism whereby adaptive myelination occurs in electrically active axons. The current
study demonstrates an increase in synaptic signalling is a feature of “pre-lesions” which may reflect a
mechanism to maintain myelin integrity and prevent lesion pathogenesis.

The current study performed transcriptomic profiling of a small number of cases (seven non-lesional
control, four “pre-lesional” and seven PVL); however, it should be acknowledged that interrogation
of 12 or more cases per group may be required to detect all of the significant differentially-expressed
genes [43]. Therefore, as some gene expression changes may not have been detected, future research
on a larger cohort of cases is required. A further limitation of the current study is the interpretation
of the transcriptomic datasets with a bias towards assessing the microglial phenotype associated with
ageing periventricular white matter pathology. The total periventricular region isolated by LCM will have
contained a heterogeneous population of cells. While several of the candidate gene expression changes are
associated with microglial functions and phenotypes, including HLA-associated transcripts, they are not
uniquely associated with microglia and may reflect changes in the transcriptomic profiles of other cells,
for example, astrocytes. Future research is required to confirm which cell population(s) are associated with
the candidate genes identified in study.

Age-associated PVL are significantly associated with cognitive decline in the ageing population,
but very little is known about the mechanisms underlying the pathology of these lesions. Overall,
our data suggest that established PVL are part of a continuous spectrum of white matter injury, and that
increased signalling in “pre-lesional” white matter may be a neuroprotective mechanism to prevent the
pathogenesis of PVL. Future studies focussing on these pathways is required, as they may represent a
potential therapeutic target to prevent lesion formation.
4. Materials and Methods

4.1. Human CNS Tissue

Frozen human post-mortem CNS tissue was obtained from the CF AS neuropathology cohort, following multi-centre Research Ethical Committee (REC) approval (REC Reference number 15/SW/0246, approved on 10th August 2015). While this cohort is representative of the ageing population, the current study was conducted with a case-control design, as previously described [7]. MRI of formalin fixed post-mortem coronal brain slices was used to guide case selection and sampling of the contralateral frozen hemisphere, using our previously published protocol [19]. A modified Schelten’s semi-quantitative rating [44], was used to select 7 PVL and 11 radiologically-normal-appearing control periventricular white matter cases (Table 8). All radiologically normal control samples scored 0 in both periventricular and deep subcortical regions. All PVL samples scored 3 in the periventricular MRI rating; three samples scored 0 in the deep subcortical region, three samples scored 3 and one sample scored 5.

Table 8. Cohort demographics.

| Experimental Approach | Classification | Median Age (y) (Range) | Gender (M/F) | PMD (h) (Range) |
|-----------------------|----------------|------------------------|--------------|----------------|
| Microarray            | Control (n = 11) | 84 (70–89)             | 4/7          | 11 (6–42)      |
|                       | PVL (n = 7)     | 89 (85–95)             | 3/4          | 26 (7–72)      |
| NanoString            | Control (n = 7) | 84 (70–89)             | 2/5          | 14 (6–42)      |
|                       | PVL (n = 5)     | 88 (85–95)             | 2/3          | 28 (18–72)     |

4.2. Histological Characterisation

Frozen sections (10 μm) were fixed in ice-cold acetone at 4 °C for 10 min and stained with haematoxylin and eosin (H&E) or luxol fast blue (LFB) to confirm the presence of PVL or non-lesional periventricular white matter. Previous studies have shown that PVL contain significantly high levels of MHC-II+ microglia [10]; therefore, immunohistochemistry (IHC) was performed to detect this marker of microglial activation using a standard Avidin–biotin complex-horse radish peroxidase (ABC-HRP) approach. Antibody conditions and suppliers are shown in Table 9.

Table 9. Antibody sources and conditions.

| Antibody | Isotype | Dilution (Time, Temperature) | Supplier |
|----------|---------|-----------------------------|----------|
| CD163    | Monoclonal Mouse IgG | 1:100 (1 h RT) | Bio-Rad, UK |
| CD68 (PG-M1) | Mouse, IgG3c | 1:100 (1 h RT) | Dako, UK |
| CD74     | Polyclonal Rabbit IgG | 1:200 (1 h RT) | Sigma, UK |
| CD80/B7-1 | Monoclonal Mouse IgG1 | 1:20 (overnight 4 °C) | R&D Systems, UK |
| CD86/B7-2 | Polyclonal goat IgG | 1:20 (overnight 4 °C) | R&D Systems, UK |
| CX3CR1   | Monoclonal Mouse IgG1 | 1:25 (overnight 4 °C) | Biolegend, UK |
| IL-1β    | Polyclonal Rabbit IgG | 1:200 (1 h RT) | Proteintech, UK |
| MHC-II (HLA-DR) | Mouse Monoclonal IgG | 1:20 (1 h RT) | Dako, UK |

Key: h: hour; RT: room temperature; IL-1β: interleukin 1 beta; κ: Kappa.

4.3. Laser Capture Microdissection (LCM)

Cryosections (10 μm) were fixed in ice-cold acetone for 3 min before staining with Toluidine blue and rinsing with diethylpyrocarbonate (DEPC)-treated water, for 30 s each. Sections were dehydrated in a graded series of ethanol (70%, 95%, 100% for 15 s each), cleared in xylene and left to air dry in an air flow hood for at least 60 min before LCM. The periventricular region of interest was isolated using a PixCell II laser-capture microdissection system (Arcturus BioScience, Mountain View, CA, USA), and CapSure macro
Int. J. Mol. Sci. 2020, 21, 7924

caps (Arcturus Engineering, Mountain View, CA, USA). Briefly, LCM of the periventricular white matter was performed using 30 µm laser spot size and a pulse power of 65–90 mW. Following microdissection, RNA was extracted using the PicoPure RNA extraction kit, according to manufacturer’s protocol (Arcturus BioScience, Mountain View, CA, USA). Pre- and post-LCM RNA quality was assessed using a Bioanalyser (Agilent, CA, USA).

4.4. Microarray

RNA was prepared according to the GeneChip 3′ IVT express amplification protocol (Affymetrix, Stockport, UK). RNA was reverse transcribed to produce single-stranded cDNA by annealing the total RNA with an oligo-d(T) primer with a T7 polymerase binding site. The cDNA was converted into double-stranded cDNA by DNA polymerase and RNase H. Biotin-labelled cRNA was made using an in vitro transcription (IVT) labelling kit. Following clean-up and purification of the biotin labelled cRNA, samples were checked using the bioanalyzer to ensure sufficient RNA had been generated (Agilent Bioanalyzer 2100). Samples (12 µg) were analysed using GeneChip Human U133 Plus 2.0 arrays (Affymetrix, Stockport, UK).

4.5. Transcriptomic Analysis of Microarrays

Quality control (QC) analysis was performed to confirm amplification, hybridisation, expression of housekeeping genes and signal intensity using Affymetrix Expression Console software (Affymetrix®, Stickport, UK). Transcriptome Analysis Console (TAC) software version 4.1.1 (Affymetrix®, Stockport, UK) was used to analyse and compare the gene expression profile of the 3 groups. Genes were considered significantly differentially expressed if they showed a minimum fold change (FC) ≥ +/−1.2 and p ≤ 0.05. Qlucore Omics Explorer (Qlucore, Lund, Sweden) was used to identify the distribution of the samples using principal component analysis (PCA). The significantly differentially-expressed genes were analysed using the Database for Annotation Visualisation and Integrated Discovery (DAVID) annotation website version 6.8, identifying the key gene expression changes in both pathways and functional groups. Annotated genes were filtered using the highest stringency settings to obtain high specificity and minimizing the rate of false-positives. Subsequent analysis focussed on the top 1000 differentially-expressed genes from each comparison group, and they were analysed using EnrichR, an online tool which aids clustering of the genes based on their similar functions. Affymetrix probe IDs were converted into Entrez Gene IDs using Database for Annotation, Visualisation and Integrated Discovery (DAVID) version 6.8 Gene ID conversion tool (david.ncifcrf.gov).

4.6. Deconvolution of the Microglial Transcriptome

To interrogate microglial function within the periventricular region, we performed a computational deconvolution of the transcriptomic data [45]. We used cell-type-specific markers for activated and inactivated microglia based on single-cell mass cytometry of the experimental allergic encephalomyelitis mouse model [24], as shown in Table 10. These markers were used to define co-expression networks which were constructed in GeneMANIA (http://www.genemania.org). The parameters used were as follows: maximum resultant genes: 20; maximum resultant attributes: 10; and the co-expression category used for gene interconnection [46]. As a final validation, co-expression networks focussed on microglial subtypes associated with human CNS cells using an independent dataset (http://www.brainrnaseq.org/) [47].
Table 10. Microglial gene signature: Group A (inactivated) and Group B (activated).

| Group        | Gene Symbol | Gene Name                                         |
|--------------|-------------|---------------------------------------------------|
| Group A      | CD317 (BST2)| Bone marrow stromal cell antigen 2                |
|              | CD39 (ENTPD1)| Ectonucleoside Triphosphate Diphosphohydrolase 1 |
|              | HLA-DRA     | Major Histocompatibility Complex, Class II, DR Alpha |
|              | CD86        | Cluster of differentiation 86                     |
|              | CD80        | Cluster of differentiation 80                     |
|              | CD274       | Cluster of differentiation 274                    |
| Group B      | CD11C (ITGAX)| Integrin Subunit Alpha X                          |
|              | TIMD4       | T Cell Immunoglobulin and Mucin Domain Containing 4 |
|              | TREM2       | Triggering Receptor Expressed on Myeloid Cells 2  |
|              | CCR5        | C-C chemokine receptor type 5                     |
|              | MRC1        | Mannose Receptor C-Type 1                         |

4.7. Validation of Gene Expression Changes—NanoString

Validation of key changes in the gene expression profiles identified by the microarray analysis was conducted using NanoString, an independent platform which enables the quantification of mRNA without the use of reverse transcription or amplification of cDNA [35]. The gene expression profiles of 9 samples (4 control and 5 PVL) were analysed using a customised CodeSet human gene panel consisting of 29 inflammation, antigen processing and presentation related genes, and 3 housekeeping genes (NanoString Technologies, Seattle, WA, USA), as shown in Table 11. Briefly, 50 ng of RNA extracted from each LCM-ed periventricular white matter region was added to the CodeSet in hybridisation buffer and incubated at 65 °C for 22 h in a thermocycler. Raw data (RCC files) were analysed using NanoString data analysis software nSolver v4.0.70 (NanoString Technologies, Seattle, WA, USA). Data were normalized to the geometric mean of housekeeping genes in the designed CodeSet. Both the Affymetrix and NanoString datasets were compared to assess expression of the validation candidates.

Table 11. Nanostring validation candidates.

| Function                             | Gene Symbol | Gene Name                                      |
|--------------------------------------|-------------|------------------------------------------------|
| Inflammation                         | AKT3        | V-akt murine thymoma viral oncogene homolog 3/RAC-gamma |
|                                      | CCL2        | C-C motif chemokine ligand 2                   |
|                                      | CCL3        | C-C motif chemokine ligand 3                   |
|                                      | CCL4        | C-C motif chemokine ligand 4                   |
|                                      | CCR5        | C-C motif chemokine receptor 5 (gene/pseudogene) |
|                                      | COL6A3      | Collagen type VI alpha chain                   |
|                                      | CX3CR1      | C-X3-C motif chemokine receptor 1              |
|                                      | IFNAR1      | Interferon alpha and beta receptor subunit 1   |
|                                      | IKBKB       | Inhibitor of nuclear factor kappa B kinase subunit beta |
|                                      | IL1A        | Interleukin 1 alpha                            |
|                                      | IL1B        | Interleukin 1 beta                             |
|                                      | JUN         | Jun proto-oncogene, AP-1 transcription factor subunit |
|                                      | PTGS2       | Prostaglandin-endoperoxide synthase 2          |
| Antigen processing and presentation  | CD74        | CD74 molecule, HLA class II histocompatibility antigen gamma chain |
|                                      | HLA-DRA     | Major histocompatibility complex, class II, DR alpha |
|                                      | CD8A        | CD8a molecule, T-cell surface glycoprotein CD8 alpha chain |
|                                      | CD163       | CD163 molecule, Scavenger Receptor Cysteine-Rich Type 1 Protein M130 |
| CD14 Monocytes                       | EPSTI1      | Epithelial stromal interaction protein 1       |
|                                      | FGL2        | Fibrinogen like 2                              |
|                                      | FPR1        | Formyl peptide receptor 1                      |
|                                      | IGSF6       | Immunoglobulin superfamily member 6            |
|                                      | PHF21A      | PHD finger protein 21A                         |
### Table 11. Cont.

| Function            | Gene Symbol | Gene Name                                      |
|---------------------|-------------|-----------------------------------------------|
| Inactivated Microglia | IRF7        | Interferon regulatory factor 7                 |
|                     | OAS1        | 2′-5′-oligoadenylate synthetase 1             |
|                     | RSAD2       | Radical S-adenosyl methionine domain containing 2|
| Activated Microglia  | FCER1G       | Fc fragment of IgE receptor Ig                |
|                     | MSR1        | Macrophage scavenger receptor 1               |
|                     | SLAMF8      | SLAM family member 8                          |
|                     | CYBB        | Cytochrome b-245, beta polypeptide            |
| Housekeeping Genes  | ACTB        | Actin cytoplasmic 1                           |
|                     | GAPDH       | Glyceraldehyde-3-phosphate dehydrogenase      |
|                     | RPLP0       | 60S acidic ribosomal protein P0               |

4.8. Validation of Gene Expression Changes—Immunohistochemistry

To further validate the gene expression changes identified in the microarray analysis, expression of the protein encoded by a panel of candidate genes was assessed by immunohistochemistry using a standard ABC-HRP approach. The antibody details are shown in Table 9. Selected regions of interest were marked on H&E sections and mapped onto consecutive immunostained slides. Quantification of specific immunoreactivity was performed by capturing bright-field microscopic images within the marked area using a Nikon Eclipse 80i microscope. The image was thresholded and the immunoreactive area of the field determined per total area examined. Image capture and analysis was performed using Analysis®D software (Nikon, Kingston Upon Thames, UK). Immunohistochemical data were not normally distributed and did not show equality of variances between groups using the Shapiro–Wilk test; therefore, analyses were performed using non-parametric methods. Statistical comparisons of quantitative data between groups were carried out using the Kruskal–Wallis test using SPSS software version 26.0 (SPSS Inc., Chicago, IL, USA). In the case of a significant result, the p value was adjusted for multiple testing using the Bonferroni correction method and considered significant if \( p < 0.05 \).

**Supplementary Materials:** Supplementary Materials can be found at [http://www.mdpi.com/1422-0067/21/21/7924/s1](http://www.mdpi.com/1422-0067/21/21/7924/s1).

**Author Contributions:** Conceptualisation, J.E.S. and S.B.W.; methodology, M.M.F.; validation, M.M.F., J.M.K., H.A.A.-A., Z.A. and T.S.; formal analysis, M.M.F., J.C.-K., P.R.H., J.E.S. and S.B.W.; writing—original draft preparation, M.M.F. and J.E.S.; writing—review and editing, S.B.W., P.H., J.C.-K., J.M.K., H.A.A.-A., Z.A., T.S., C.B. and F.E.M.; supervision, J.E.S. and S.B.W. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by a scholarship from King Abdulaziz University (KAU) awarded to M.M.F. S.B.W. received funding from the Alzheimer’s Society (AS PG17-007) and Alzheimer’s Research UK (ARUK PG 2019A-003). Work in the individual CFAS centres is supported by the UK NIHR Biomedical Research Centre for Ageing and Ageing—awarded to the Newcastle upon Tyne Hospitals Foundation Trust; the Cambridge Brain Bank supported by the NIHR Cambridge Biomedical Research Centre; Nottingham University Hospitals NHS Trust; University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust and the Sheffield NIHR Biomedical Research Centre; The Thomas Willis Oxford Brain Collection, supported by the Oxford Biomedical Research Centre; The Walton Centre NHS Foundation Trust, Liverpool.

**Acknowledgments:** C.F.A.S. would like to acknowledge the essential contributions of the liaison officers; the general practitioners; their staff; and nursing and residential home staff. We are grateful to our respondents and their families for their generous gift to medical research, which has made this study possible.

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

- **ABC-HRP** avidin-biotin complex-horse radish peroxidase
- **ACTB** actin cytoplasmic 1
- **AKT3** V-akt murine thymoma viral oncogene homolog 3
BBB    blood brain-barrier
BST2   CD317, tethrin
CACNA1E calcium voltage-gated channel subunit alpha 1E
CALM   calmodulin
CAMK2A calcium/calmodulin-dependent protein kinase II alpha
CAMK4  calcium/calmodulin-dependent protein kinase IV
cAMP   cyclic adenosine monophosphate
CCL2   C-C motif chemokine ligand 2
CCL3   C-C motif chemokine ligand 3
CCL4   C-C motif chemokine ligand 4
CCR5   C-C motif chemokine receptor 5 (gene/pseudogene)
CD163  CD163 molecule, Scavenger Receptor Cysteine-Rich Type 1 Protein M130
CD274  cluster of differentiation 274, programmed death-ligand 1
CD74   CD74 molecule, HLA class II histocompatibility antigen gamma chain
CD80   co-stimulatory molecule B7-2
CD86   cluster of differentiation 86, B7-2
CD8A   CD8a molecule, T-cell surface glycoprotein CD8 alpha chain
cDNA   complementary DNA
CFAS   Cognitive Function and Ageing Study
CNS    central nervous system
COL6A3 collagen type VI alpha 3 chain
CX3CR1 C-X3-C motif chemokine receptor 1
CYBB   cytochrome b-245, beta polypeptide
DAVID  Database for Annotation, Visualization and Integrated Discovery
DEPC   diethylpyrocarbonate
DSCL   deep subcortical lesions
ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1
EPSTI1 epithelial stromal interaction protein 1
FCER1G Fc fragment of IgE receptor Ig
FCGR1A Fc fragment of immunoglobulin gamma Fc receptor 1A
FCGR2A Fc fragment of immunoglobulin gamma Fc receptor 2A
FGL2   fibrinogen like 2
FPR1   formyl peptide receptor 1
GABA   gamma-aminobutyric acid
GAPDH  glyceraldehyde-3-phosphate dehydrogenase
GBP5   guanylate-binding protein 5
GEO    gene expression omnibus
GRIA   glutamate receptor, ionotropic, AMPA
GRIN1  glutamate receptor, ionotropic, N-methyl D-aspartate 1
H&E    haematoxylin and eosin
HAVCR2 hepatitis A virus cellular receptor 2
HLA-DMB major histocompatibility complex, class II, DM beta
HLA-DPA1 major histocompatibility complex, class II, DP alpha 1
HLA-DPB1 major histocompatibility complex, class II, DP beta 1
HLA-DQB1 major histocompatibility complex, class II, DQ beta 1
HLA-DRA major histocompatibility complex, class II, DR alpha
IFI35  interferon induced protein 35
IFI44  interferon induced protein 44
IFI44L interferon induced protein 44-like
IFIT1  interferon induced protein with tetratricopeptide repeats 1
IFIT3 interferon induced protein with tetratricopeptide repeats 3
IFNAR1 interferon alpha receptor subunit 1
IGSF6 immunoglobulin superfamily member 6
IHC immunohistochemistry
IKBKB inhibitor of nuclear factor kappa B kinase subunit beta
IL1A interleukin 1 alpha
IL1B interleukin 1 beta
IRF7 interferon regulatory factor 7
IRF9 interferon regulatory factor 9
ISG15 interferon-stimulated gene 15
ITGAX integrin, alpha X (complement component 3 receptor 4 subunit), CD11c
IVT in vitro transcription
JUN jun proto-oncogene, AP-1 transcription factor subunit
KEGG Kyoto Encyclopedia of Genes and Genomes
LCM laser capture microdissection
LCP2 lymphocyte cytosolic protein 2
LFB luxol fast blue
LY6E lymphocyte antigen 6E
MAPK mitogen-activated protein kinase
MHC-II major histocompatibility complex class II
MRC1 mannose receptor C-type 1
MRI magnetic resonance imaging
mRNA messenger ribonucleic acid
MS4A6A membrane spanning 4-domains A6A
MSR1 macrophage scavenger receptor 1
MX1 MX dynamin like GTPase 1
OAS1 2’-5’-oligoadenylate synthetase 1
OAS2 2’-5’-oligoadenylate synthetase 2
OAS3 2’-5’-oligoadenylate synthetase 3
PCA principal component analysis
PHF21A PHD finger protein 21A
PI3K-Akt phosphatidylinositol 3-kinase-protein kinase
PTGS2 prostaglandin-endoperoxide synthase 2
PVL periventricular lesions
QC quality control
REC research ethics committee
RPLP0 60S acidic ribosomal protein P0
RSAD2 radical S-adenosyl methionine domain containing 2
RT room temperature
SAMSN1 SAM domain, SH3 domain and nuclear localisation signals 1
SLAMF8 SLAM family member 8
TAC transcriptome analysis console
TFEC transcription factor EC
TREM2 triggering receptor expressed on myeloid cells 2
UBE2L6 ubiquitin conjugating enzyme E2 L6
USP18 ubiquitin specific peptidase 18
WM white matter
WML white matter lesions
XAF1 XIAP-associated factor 1
References

1. Prins, N.D.; Scheltens, P. White matter hyperintensities, cognitive impairment and dementia: An update. *Nat. Rev. Neurol.* 2015, 11, 157–165. [CrossRef]

2. Fernando, M.S.; Ince, P.G.; Function, M.R.C.C. Ageing Neuropathology Study G: Vascular pathologies and cognition in a population-based cohort of elderly people. *J. Neurol. Sci.* 2004, 226, 13–17. [CrossRef]

3. Matthews, F.E.; Brayne, C.; Lowe, J.; McKeith, I.; Wharton, S.B.; Ince, P. Epidemiological pathology of dementia: Attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. *PLoS Med.* 2009, 6, e1000180. [CrossRef]

4. Wang, Y.L.; Chen, W.; Cai, W.J.; Hu, H.; Xu, W.; Wang, Z.T.; Cao, X.P.; Tan, L.; Yu, J.T. Alzheimer’s Disease Neuroimaging I: Associations of White Matter Hyperintensities with Cognitive Decline: A Longitudinal Study. *J. Alzheimers Dis.* 2020, 73, 759–768. [CrossRef]

5. Biesbroek, J.M.; Weaver, N.A.; Biessels, G.J. Lesion location and cognitive impact of cerebral small vessel disease. *Clin. Sci.* 2017, 131, 715–728. [CrossRef]

6. Gouw, A.A.; Seewann, A.; van der Flier, W.M.; Barkhof, F.; Rozemuller, A.M.; Scheltens, P.; Geurts, J.J. Heterogeneity of small vessel disease: A systematic review of MRI and histopathology correlations. *J. Neurol. Neurosurg. Psychiatry* 2011, 82, 126–135. [CrossRef]

7. Wharton, S.B.; Simpson, J.E.; Brayne, C.; Ince, P.G. Age-associated white matter lesions: The MRC Cognitive Function and Ageing Study. *Brain Pathol.* 2015, 25, 35–43. [CrossRef]

8. Alber, J.; Alladi, S.; Bae, H.J.; Barton, D.A.; Beckett, L.A.; Bell, J.M.; Berman, S.E.; Biessels, G.J.; Black, S.E.; Bos, I.; et al. White matter hyperintensities in vascular contributions to cognitive impairment and dementia (VCID): Knowledge gaps and opportunities. *Alzheimers Dement.* 2019, 5, 107–117. [CrossRef] [PubMed]

9. Hashemimaghdam, A.; Mroczek, M. Microglia heterogeneity and neurodegeneration: The emerging paradigm of the role of immunity in Alzheimer’s disease. *J. Neuroimmunol.* 2020, 341, 577185. [CrossRef] [PubMed]

10. Simpson, J.E.; Ince, P.G.; Higham, C.E.; Gelsthorpe, C.H.; Fernando, M.S.; Matthews, F.; Forster, G.; O’Brien, J.T.; Barber, R.; Kalaria, R.N.; et al. Microglial activation in white matter lesions and nonlesional white matter of ageing brains. *Neuropathol. Appl. Neurobiol.* 2007, 33, 670–683. [CrossRef]

11. Simpson, J.E.; Fernando, M.S.; Clark, L.; Ince, P.G.; Matthews, F.; Forster, G.; O’Brien, J.T.; Barber, R.; Kalaria, R.N.; Brayne, C.; et al. White matter lesions in an unselected cohort of the elderly: Astrocytic, microglial and oligodendrocyte precursor cell responses. *Neuropathol. Appl. Neurobiol.* 2007, 33, 410–419. [CrossRef] [PubMed]

12. Waller, R.; Baxter, L.; Fillingham, D.J.; Coelho, S.; Pozo, J.M.; Mozumder, M.; Frangi, A.F.; Ince, P.G.; Simpson, J.E.; Highley, J.R. Iba-1+/CD68+ microglia are a prominent feature of age-associated deep subcortical white matter lesions. *PLoS ONE* 2019, 14, e0210888. [CrossRef]

13. Fernando, M.S.; Simpson, J.E.; Matthews, F.; Brayne, C.; Lewis, C.E.; Barber, R.; Kalaria, R.N.; Forster, G.; Esteves, F.; Wharton, S.B.; et al. White matter lesions in an unselected cohort of the elderly: Molecular pathology suggests origin from chronic hypoperfusion injury. *Stroke* 2006, 37, 1391–1398. [CrossRef] [PubMed]

14. Wong, S.M.; Jansen, J.F.A.; Zhang, C.E.; Hoff, E.I.; Staals, J.; van Oostenbrugge, R.J.; Backes, W.H. Blood-brain barrier impairment and hypoperfusion are linked in cerebral small vessel disease. *Neurology* 2019, 92, e1669–e1677. [CrossRef] [PubMed]

15. Simpson, J.E.; Wharton, S.B.; Cooper, J.; Gelsthorpe, C.; Baxter, L.; Forster, G.; Shaw, P.J.; Savva, G.; Matthews, F.E.; Brayne, C.; et al. Alterations of the blood-brain barrier in cerebral white matter lesions in the ageing brain. *Neurosci. Lett.* 2010, 486, 246–251. [CrossRef]

16. Zhang, C.E.; Wong, S.M.; Uiterwijk, R.; Backes, W.H.; Jansen, J.F.A.; Jeukens, C.; van Oostenbrugge, R.J.; Staals, J. Blood-brain barrier leakage in relation to white matter hyperintensity volume and cognition in small vessel disease and normal aging. *Brain Imaging Behav.* 2019, 13, 389–395. [CrossRef]

17. Frieze, W.M.; Jacobs, H.L.; de Jong, J.J.; Verheggen, I.C.M.; Gronenschild, E.; Palm, W.M.; Hoff, E.I.; Wardlaw, J.M.; Jansen, J.F.A.; Verhey, F.R.; et al. White matter hyperintensities mediate the association between blood-brain barrier leakage and information processing speed. *Neurobiol. Aging* 2020, 85, 113–122. [CrossRef]
18. McAleese, K.E.; Walker, L.; Graham, S.; Moya, E.L.J.; Johnson, M.; Erskine, D.; Colloby, S.J.; Dey, M.; Martin-Ruiz, C.; Taylor, J.P.; et al. Parietal white matter lesions in Alzheimer’s disease are associated with cortical neurodegenerative pathology, but not with small vessel disease. *Acta Neuropathol.* 2017, 134, 459–473. [CrossRef]

19. Simpson, J.E.; Hosny, O.; Wharton, S.B.; Heath, P.R.; Holden, H.; Fernando, M.S.; Matthews, F.; Forster, G.; O’Brien, J.T.; Barber, R.; et al. Microarray RNA expression analysis of cerebral white matter lesions reveals changes in multiple functional pathways. *Stroke* 2009, 40, 369–375. [CrossRef]

20. Gupta, N.; Simpkins, A.N.; Hitomi, E.; Dias, C.; Leigh, R. Investigators NIHmHos: White Matter Hyperintensity-Associated Blood-Brain Barrier Disruption and Vascular Risk Factors. *J. Stroke Cerebrovasc. Dis.* 2018, 27, 466–471. [CrossRef]

21. Kloppenborg, R.P.; Nederkoorn, P.J.; Geerlings, M.I.; van den Berg, E. Presence and progression of white matter hyperintensities and cognition: A meta-analysis. *Neurology* 2014, 82, 2127–2138. [CrossRef] [PubMed]

22. Fournier, M.L.; Paulson, A.; Pavelka, N.; Mosley, A.L.; Gaudenz, K.; Bradford, W.D.; Glynn, E.; Li, H.; Sardiu, M.E.; Fleharty, B.; et al. Delayed correlation of mRNA and protein expression in rapamycin-treated cells and a role for Gpc1 in cellular sensitivity to rapamycin. *Mol. Cell Proteom.* 2010, 9, 271–284. [CrossRef] [PubMed]

23. Koussounadis, A.; Langdon, S.P.; Um, I.H.; Harrison, D.J.; Smith, V.A. Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system. *Sci. Rep.* 2015, 5, 10775. [CrossRef] [PubMed]

24. Ajami, B.; Samusik, N.; Wieghofer, P.; Ho, P.P.; Crotti, A.; Bjornson, Z.; Prinz, M.; Fantl, W.J.; Nolan, G.P.; Steinman, L. Single-cell mass cytometry reveals distinct populations of brain myeloid cells in mouse neuroinflammation and neurodegeneration models. *Nat. Neurosci.* 2018, 21, 541–551. [CrossRef] [PubMed]

25. Polyak, M.J.; Vivithanaporn, P.; Maingat, F.G.; Walsh, J.G.; Branton, W.; Cohen, E.A.; Meeker, R.; Power, C. Differential type I interferon-regulated gene expression in the brain during AIDS: Interactions with viral diversity and neurovirulence. *FASEB J.* 2013, 27, 2829–2844. [CrossRef]

26. Rodriguez-Gomez, J.A.; Kavanagh, E.; Engskog-Vlachos, P.; Engskog, M.K.R.; Herrera, A.J.; Espinosa-Obiva, A.M.; Joseph, B.; Hajji, N.; Venero, J.L.; Burguillos, M.A. Microglia: Agents of the CNS Pro-Inflammatory Response. *Cells* 2020, 9, 1717. [CrossRef] [PubMed]

27. Yin, Z.; Raj, D.; Saiepour, N.; Van Dam, D.; Brouwer, N.; Holtman, I.R.; Egggen, B.J.L.; Moller, T.; Tamm, J.A.; Abdourahman, A.; et al. Immune hyperreactivity of Abeta plaque-associated microglia in Alzheimer’s disease. *Neurobiol. Aging* 2017, 55, 115–122. [CrossRef]

28. Baron, R.; Babcock, A.A.; Nemirovsky, A.; Finsen, B.; Monsonego, A. Accelerated microglial pathology is associated with Abeta plaques in mouse models of Alzheimer’s disease. *Aging Cell* 2014, 13, 584–595. [CrossRef]

29. Busse, S.; Steiner, J.; Alter, J.; Dobrowolny, H.; Mawrin, C.; Bogerts, B.; Hartig, R.; Busse, M. Expression of HLA-DR, CD80, and CD86 in Healthy Aging and Alzheimer’s Disease. *J. Alzheimers Dis.* 2015, 47, 177–184. [CrossRef]

30. Li, T.; Zhu, J. Entanglement of CCR5 and Alzheimer’s Disease. *Front. Aging Neurosci.* 2019, 11, 209. [CrossRef]

31. Roy, E.R.; Wang, B.; Wan, Y.W.; Chiu, G.; Cole, A.; Yin, Z.; Props, N.; Xu, Y.; Jankowsky, J.L.; Liu, Z.; et al. Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. *J. Clin. Investig.* 2020, 130, 1912–1930. [CrossRef] [PubMed]

32. Sebastian Monasor, L.; Muller, S.A.; Colombo, A.V.; Tanriover, G.; Konig, J.; Roth, S.; Liesz, A.; Berghofer, A.; Piechotta, A.; Prestel, M.; et al. Fibrillar Abeta triggers microglial proteome alterations and dysfunction in Alzheimer mouse models. *Elife* 2020, 9, e54083. [CrossRef]

33. Askew, K.; Gomez-Nicola, D. A story of birth and death: Insights into the formation and dynamics of the microglial population. *Brain Behav. Immun.* 2018, 69, 9–17. [CrossRef]

34. Friedman, B.A.; Srinivasan, K.; Ayalon, G.; Meilandt, W.J.; Lin, H.; Huntley, M.A.; Cao, Y.; Lee, S.H.; Haddick, P.C.G.; Ng, H.; et al. Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer’s Disease Not Evident in Mouse Models. *Cell Rep.* 2018, 22, 832–847. [CrossRef] [PubMed]
35. Eastel, J.M.; Lam, K.W.; Lee, N.L.; Lok, W.Y.; Tsang, A.H.F.; Pei, X.M.; Chan, A.K.C.; Cho, W.C.S.; Wong, S.C.C. Application of NanoString technologies in companion diagnostic development. Expert Rev. Mol. Diagn. 2019, 19, 591–598. [CrossRef]

36. Simpson, J.E.; Newcombe, J.; Cuzner, M.L.; Woodroofe, M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 1998, 84, 238–249. [CrossRef]

37. Buschmann, J.P.; Berger, K.; Awad, H.; Clarner, T.; Beyer, C.; Kipp, M. Inflammatory response and chemokine expression in the white matter corpus callosum and gray matter cortex region during cuprizone-induced demyelination. J. Mol. Neurosci. 2012, 48, 66–76. [CrossRef]

38. Cui, L.Y.; Chu, S.F.; Chen, N.H. The role of chemokines and chemokine receptors in multiple sclerosis. Int. Immunopharmacol. 2020, 83, 106314. [CrossRef] [PubMed]

39. Baltan, S. Ischemic injury to white matter: An age-dependent process. Neuroscientist 2009, 15, 126–133. [CrossRef] [PubMed]

40. Doyle, S.; Hansen, D.B.; Vella, J.; Bond, P.; Harper, G.; Zammit, C.; Valentino, M.; Fern, R. Vesicular glutamate release from central axons contributes to myelin damage. Nat. Commun. 2018, 9, 1032. [CrossRef]

41. Karadottir, R.; Cavelier, P.; Bergersen, L.H.; Attwell, D. NMDA receptors are expressed in oligodendrocytes and activated in ischaemia. Nature 2005, 438, 1162–1166. [CrossRef]

42. Fields, R.D. A new mechanism of nervous system plasticity: Activity-dependent myelination. Nat. Rev. Neurosci. 2015, 16, 756–767. [CrossRef]

43. Schurch, N.J.; Schofield, P.; Gierlinski, M.; Cole, C.; Sherstnev, A.; Singh, V.; Wrobel, N.; Gharbi, K.; Simpson, G.G.; Owen-Hughes, T.; et al. How many biological replicates are needed in an RNA-seq experiment and which differential expression tool should you use? RNA 2016, 22, 839–851. [CrossRef]

44. Scheltens, P.; Barkhof, F.; Leys, D.; Pruvo, J.P.; Nauta, J.J.; Vermersch, P.; Steinling, M.; Valk, J. A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. J. Neurol. Sci. 1993, 114, 7–12. [CrossRef]

45. Avila Cobos, F.; Vandesompele, J.; Mestdagh, P.; De Preter, K. Computational deconvolution of transcriptomics data from mixed cell populations. Bioinformatics 2018, 34, 1969–1979. [CrossRef]

46. Warde-Farley, D.; Donaldson, S.L.; Comes, O.; Zuberi, K.; Badrawi, R.; Chao, P.; Franz, M.; Grouios, C.; Kazi, F.; Lopes, C.T.; et al. The GeneMANIA prediction server: Biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010, 38, W214–W220. [CrossRef]

47. Zhang, Y.; Sloan, S.A.; Clarke, L.E.; Caneda, C.; Plaza, C.A.; Blumenthal, P.D.; Vogel, H.; Steinberg, G.K.; Edwards, M.S.; Li, G.; et al. Purification and Characterization of Progenitor and Mature Human Astrocytes Reveals Transcriptional and Functional Differences with Mouse. Neuron 2016, 89, 37–53. [CrossRef]